<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
</head>
<body><p><strong>11. Chronic Hepatitis</strong></p><p>This refers to chronic inflammation of the liver of more than 6 months duration, with persistently elevated liver function tests. Chronic hepatitis can progress to liver cirrhosis, portal hypertension with upper gastrointestinal bleeding, hepatic encephalopathy and hepatocellular carcinoma.</p><p>Immunisation against Hepatitis B is now available for children under the Expanded Programme on Immunisation (EPI). Adults in endemic areas including Ghana should be immunised against Hepatitis B infection after initial assessment of their immunological status regarding previous exposure to the virus.</p><p>Long-term monitoring for disease activity and hepatocellular carcinoma screening with six-monthly Hepatitis B viral DNA quantification, LFTs, abdominal ultrasound and alpha fetoprotein is mandatory for patients with chronic hepatitis B.</p><p> </p><p><strong>CAUSES</strong></p><ul><li>Hepatitis B virus (HBV)</li><li>Hepatitis C virus (HCV)</li><li>Hepatitis E virus (genotype 3)</li></ul><p> </p><p><strong>SYMPTOMS</strong></p><ul><li>Usually, asymptomatic</li><li>Mild non-specific symptoms</li><li>Recurrent fever</li><li>Arthralgia</li><li>Malaise</li><li>Jaundice</li><li>Lethargy</li></ul><p> </p><p><strong>SIGNS</strong></p><p><strong>Stigmata of chronic liver disease</strong></p><ul><li>Palmar erythema</li><li>Clubbing</li><li>Dupuytren's contracture</li><li>Parotid enlargement</li><li>Gynaecomastia</li><li>Testicular atrophy</li><li>Spider naevi</li></ul><p> </p><p><strong>Signs of decompensated liver disease</strong></p><ul><li>Jaundice</li><li>Ascites</li><li>Encephalopathy</li><li>Peripheral oedema (hypoalbuminaemia)</li><li>Purpura/skin bruising (coagulopathy)</li></ul><p> </p><p><strong>INVESTIGATIONS</strong></p><ul><li>FBC</li><li>LFTs</li><li>INR</li><li>HIV</li><li>Baseline Alpha-Feto-protein</li><li>Abdominal ultrasound scan</li><li>Liver biopsy</li></ul><p> </p><p><strong>Chronic Hepatitis B</strong></p><ul><li>Hepatitis B surface Antigen (HBsAg)</li><li>HBc IgG</li><li>Hepatitis-B-e-antigen (HBeAg) &amp; Anti-HBe</li><li>Hepatitis B Viral Load</li></ul><p> </p><p><strong>Chronic Hepatitis C</strong></p><ul><li>Hepatitis C Virus (HCV) antibody testing</li><li>HCV RNA</li><li>HCV genotyping </li></ul><p> </p><p><strong>TREATMENT</strong> </p><p><strong>Treatment objectives</strong></p><ul><li>To prevent disease progression and complications</li><li>To prevent hepatic encephalopathy</li><li>To improve synthetic liver function through viral suppression</li><li>To prevent transmission</li></ul><p> </p><p><strong>Non-pharmacological treatment</strong></p><ul><li>Prevention of transmission to partners (e.g. protected sex, not sharing of toothbrushes and sharps, blades, needles, body piercings, tattoos, cultural scarification practices, circumcisions etc.)</li><li>Lifestyle/dietary advice</li><li>Spouse/household screening</li></ul><p> </p><p><strong>Pharmacological treatment</strong></p><p><strong>A. Chronic Active Hepatitis B (HBeAg positive or HBeAg negative)</strong></p><p><strong>1st Line Treatment </strong></p><p>Evidence Rating: [A]</p><ul><li>Pegylated Interferon alfa-2a, subcutaneous,</li></ul><p><strong>Or</strong></p><p>•  Tenofovir, oral,</p><p><strong>  Or</strong></p><p>•  Entecavir, oral,</p><p><strong>2nd Line Treatment </strong></p><p>Evidence Rating: [A]</p><p>•  Lamivudine, oral,</p><p> </p><p><strong>B. Decompensated liver cirrhosis/ Fulminant Liver failure from</strong></p><p><strong>Chronic Hepatitis B</strong></p><p><strong>1st Line Treatment </strong></p><p>Evidence Rating: [A]</p><p>•  Tenofovir, oral,</p><p><strong>Or</strong></p><p>•  Entecavir, oral,</p><p><strong>2nd Line Treatment </strong></p><p>Evidence Rating: [A]</p><p>•  Lamivudine, oral,</p><p><strong>C. Patients with Chronic Hepatitis B undergoing chemotherapy or immunosuppressive treatment</strong></p><p><strong>1st Line Treatment </strong></p><p>Evidence Rating: [A]</p><p>•  Tenofovir, oral,</p><p><strong>Or</strong></p><p>•  Entecavir, oral,</p><p><strong>2nd Line Treatment </strong></p><p>Evidence Rating: [A]</p><p>•  Lamivudine, oral,</p><p> </p><p><strong>REFERRAL CRITERIA</strong></p><p>  Refer all cases of chronic hepatitis B infection to a specialist, especially those who have failed first-line anti-viral therapy or had adverse reactions to anti-viral therapy or have liver-related complications (e.g. liver cirrhosis, liver failure, liver mass, signs of portal hypertension, ascites, peripheral oedema, hypoalbuminaemia). Pregnant individuals and patients with hepatitis B co-infections (e.g. HIV/Hepatitis C) as well as those requiring chemotherapy or other immunosuppressive therapy should also be referred to a specialist.</p>
    <div style="width: 95vw;">
        <img src="https://osamfrimpong.github.io/stg_app_web/images/pep_for_hepatitisB.jpg" alt="Post exposure management of Hepatitis B" style="max-width: 100%;height: auto;margin: auto;">
        </div>
    <p>*HCW: Healthcare worker</p><p>HBIG: Hepatitis B Immunoglobulin as soon as possible when indicated (0.06 ml/kg IM)</p><p> </p><p><strong>Note 2-2</strong></p><p><strong>Anti-HBs Titre should be performed 1-2 months after last dose of HBV vaccina- tion series but ~ 4-6 months after HBIG to avoid detection of passively admin- istered Anti-HBs. Responder: person with Anti-HBs &gt; 10 MIU/ml after 3 or more HBV vaccination doses. Non-responder: person with Anti-HBs &lt; 10 MIU/ml after 6 or more HBV vaccination doses. </strong></p><p><strong>Note 2-3</strong></p><p><strong>All HCWS who have Anti-Hbs &lt; 10 MIU/ml, unvaccinated or incomplete vaccination and sustain exposure to a source patient who is HBsAg-positive/ unknown HBsAg status should undergo HBsAg screening as soon as possible after expo- sure and follow up testing ~ 6 months later (HBsAg + Anti-HBc).</strong></p><p><strong>A.  Chronic Hepatitis C (Genotype 2 &amp; 3)</strong></p><p><strong>1st Line Treatment</strong></p><p>  Evidence Rating: [A]</p><p>•  Pegylated Interferon alfa-2a, subcutaneous,</p><p><strong>Or</strong></p><p>•  Pegylated Interferon alfa-2b, subcutaneous,</p><p><strong>And</strong></p><p>•  Ribavirin, oral,</p><p><strong>B.  Chronic Hepatitis C (Genotype 1 &amp; 4)</strong></p><p><strong>1st Line Treatment </strong></p><p>Evidence Rating: [A]</p><p>•  Pegylated Interferon alfa-2a, subcutaneous,</p><p><strong>Or</strong></p><p>•  Pegylated Interferon alfa-2b, subcutaneous,</p><p><strong>And</strong></p><p>•  Ribavirin, oral,</p><p> </p><p><strong>REFERRAL CRITERIA</strong></p><p>Refer all cases of chronic hepatitis C infection to a specialist, especially those who have failed first-line anti-viral therapy or had adverse reactions to anti-viral therapy or have liver-related complications (e.g. liver cirrhosis, liver failure, liver mass, signs of portal hypertension, ascites, peripheral oedema, hypoalbuminaemia). Pregnant individuals and patients with hepatitis C co-infections (e.g. HIV/Hepatitis B) as well as those requiring chemotherapy or other immunosuppressive therapy should also be referred to a specialist.</p>
</body>
</html>
